Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
An excellent prognosis may be achieved without PORT in T1/2N0M0 mucoepidermoid carcinoma patients positive for CRTC1/3-MAML2 fusions when the tumors are completely resected without tumor spillage.
|
30475407 |
2018 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
This multi-institutional study characterizes the clinicopathologic and molecular features of this tumor by utilizing next-generation sequencing to assess common mutations and gene fusions involved in thyroid carcinogenesis as well as fluorescence in-situ hybridization for MAML2 translocations typical of salivary gland mucoepidermoid carcinoma.
|
27910944 |
2017 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Eight of nine tested tumors (89%) were positive for MECT1-MAML2.
|
28343305 |
2017 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
FISH was used to determine the presence or absence of the MECT1-MAML2 translocation in 17 tumors.
|
27340278 |
2017 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Fluorescence in situ hybridization for MAML2 break apart was analyzable in 13 specimens and in all these specimens was positive, including 4 tumors with no demonstrable CRTC1-MAML2 fusion.
|
27402217 |
2016 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this study, we showed that AREG overexpression was detected more frequently in the CRTC1-MAML2 fusion-positive tumors than in fusion-negative tumors.
|
27393417 |
2016 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Hence, gene rearrangements such as CRTC1-MAML2 in mucoepidermoid carcinomas have shown excellent specificity, and more than that, it has been strongly correlated with low-grade tumors and consequently with an increased survival rate and better prognosis of patients affected by neoplasms carrying this translocation.
|
25990369 |
2016 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
All 12 patients with tumor tissue available for testing were positive for MECT1/MAML2 fusion transcripts.
|
26221861 |
2016 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
FISH-WSI results showed that all epithelial cells harbored the MAML2 split in fusion-positive mWT-like tumors and were totally negative in fusion-negative mWT-like tumors.
|
26457352 |
2015 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
MAML2 rearrangement appears frequent in PMEC and specific with this tumor.
|
24714697 |
2014 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
To further characterize this heterogeneous group of tumors we have performed a comprehensive analysis of copy number alterations and CRTC1-MAML2 fusion status in a series of 28 mucoepidermoid carcinomas.
|
23018873 |
2013 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Mucoepidermoid carcinomas negative for CRTC1/3-MAML2 and positive for the MAML2 gene split (n = 19) showed favorable clinicopathological tumor features similar to those positive for CRTC1/3-MAML2 fusions.
|
23035786 |
2013 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
It is concluded that MECT1-MAML2 gene fusion is a highly specific genetic alteration in MEC with predominance in low-grade and intermediate-grade tumors.
|
22847156 |
2012 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Using RT-PCR and FISH we demonstrated that the tumor was positive for the CRTC1-MAML2 gene fusion previously shown to be associated with in particular low-grade salivary MECs with favorable prognosis.
|
22323114 |
2012 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The lack of significant correlation with histologic grade or pathologic stage implies that the previously reported prognostic value of the MAML2 translocation may be an artifact of misclassification of MEC as other tumors.
|
22833306 |
2012 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MEC cases positive for CRTC1-MAML2 or CRTC3-MAML2 fusion formed a favourable tumour subset that was distinct from fusion-negative cases.
|
21668476 |
2011 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Reverse transcriptase polymerase chain reaction and direct sequencing revealed CRTC1-MAML2 translocation of this tumor.
|
21676434 |
2011 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Mucoepidermoid carcinoma of the cervix: another tumor with the t(11;19)-associated CRTC1-MAML2 gene fusion.
|
19092631 |
2009 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
For overall survival, p27Kip1 expression, CRTC1-MAML2 fusion, and tumor size were significant.
|
19531414 |
2009 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We conclude that the presence of MAML2-rearrangement as well as of MECT1-MAML2 fusion transcript may reflect a more favourable prognosis and may be a useful marker for clinical prediction of the biological behavior of these tumors as previously reported.
|
19578770 |
2009 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
It is interesting to note that patients with CRTC3-MAML2-positive tumors (mean 36 years of age) were significantly younger that those with the CRTC1-MAML2 fusion (55 years) and those with fusion-negative tumors (58 years).
|
19749740 |
2009 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The t(11;19) translocation and its CRTC1/MAML2 fusion transcript have been identified in several examples of both Warthin's tumor and mucoepidermoid carcinoma and are believed to be associated with the development of a subset of these tumors.
|
18181164 |
2008 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our data concur with previously reported cases, in which t(11;19) appears to be the primary chromosomal aberration for pulmonary MEC in children, and that the MECT1-MAML2 fusion transcript is associated with a better prognosis in MEC tumors.
|
17618868 |
2007 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Our findings thus demonstrate that the CRTC1-MAML2 gene fusion is frequent in hidradenomas and is associated with clear cell variants of this tumor.
|
17334997 |
2007 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We analyzed 55 primary salivary gland tumors including 22 mucoepidermoid carcinomas (MECs) to determine the association of MECT1/TORC1/CRTC1-MAML2 fusion transcript to tumor types, level of MEC differentiation and clinicopathologic parameters.
|
17437281 |
2007 |